Ibritumomab tiuxetan is a targeted therapy that combines a monoclonal antibody (ibritumomab) with a radioactive substance (Yttrium-90). The antibody specifically binds to the CD20 antigen, which is found on the surface of most B-cells, including cancerous B-cells in non-Hodgkin’s lymphoma (NHL).

Once attached to the CD20 antigen, the radioactive Yttrium-90 delivers localized radiation directly to the cancerous B-cells and nearby cells. This radiation causes cellular damage and death, helping to reduce or eliminate the lymphoma cells. The targeted nature of this therapy allows for a focused attack on cancer cells while limiting damage to surrounding healthy tissues.

After treatment, there is a significant reduction in circulating B-cells, which gradually recover over several months. This approach is particularly effective in treating certain types of B-cell non-Hodgkin’s lymphoma, especially when other treatments have not worked or as a consolidation after initial chemotherapy.

Ibritumomab tiuxetan

Common brand names

Approved use in